BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating a resolvin therapeutic, RX-10045, in a Phase I/II clinical trial in patients with moderate-severe dry eye syndrome. RX-10045 is a synthetic analog of RvE1, a naturally occurring resolvin with potent anti-inflammatory and cell-sparing activities in laboratory testing.
